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ABSTRACT 
Fractures are frequent in patients receiving hemodialysis. We tested the hypothesis that cinacalcet would 
reduce the rate of clinical fractures in patients receiving hemodialysis using data from the Evaluation of 
Cinacalcet HCl Therapy to Lower Cardiovascular Events trial, a placebo-controlled trial that randomized 
3883 hemodialysis patients with secondary hyperparathyroidism to receive cinacalcet or placebo for #64 
months. This study was a prespeciﬁed secondary analysis of the trial whose primary end point was all-cause 
mortality and non-fatal cardiovascular events, and one of the secondary end points was ﬁrst clinical frac- 
ture event. Clinical fractures were observed in 255 of 1935 (13.2%) patients randomized to placebo and 
238 of 1948 (12.2%) patients randomized to cinacalcet. In an unadjusted intention-to-treat analysis, the 
relative hazard for fracture (cinacalcet versus placebo) was 0.89 (95% conﬁdence interval [95% CI], 0.75 to 
1.07). After adjustment for baseline characteristics and multiple fractures, the relative hazard was 0.83 
(95% CI, 0.72 to 0.98). Using a prespeciﬁed lag-censoring analysis (a measure of actual drug exposure), the 
relative hazard for fracture was 0.72 (95% CI, 0.58 to 0.90). When participants were censored at the time of 
cointerventions (parathyroidectomy, transplant, or provision of commercial cinacalcet), the relative hazard 
was 0.71 (95% CI, 0.58 to 0.87). Fracture rates were higher in older compared with younger patients and 
the effect of cinacalcet appeared more pronounced in older patients. In conclusion, using an unadjusted 
intention-to-treat analysis, cinacalcet did not reduce the rate of clinical fracture. However, when account- 
ing for differences in baseline characteristics, multiple fractures, and/or events prompting discontinuation 
of study drug, cinacalcet reduced the rate of clinical fracture by 16%–29%. 
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Patients with end stage renal disease (ESRD) on di- 
alysis have increased risk of fractures compared with 
the general population.1  Fracture incidence rates 
vary by geographic region, although rates are con- 
sistently higher in patients with CKD than matched 
controls from the same country.2–6  Depending on 
the study, 10%–52% of patients receiving dialysis 
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have experienced one or more fractures (reviewed in Kaji 
et al.2 and Kidney Disease Improving Global Outcomes7). In 
nondialysis populations, secondary analyses of fracture stud- 
ies show increased rates in patients with eGFRs,60 ml/min 
per 1.73 m
2
.8,9   Risk factors associated with fractures in pa- 
tients with CKD include older age, female sex, lower serum 
albumin, prior kidney transplantation, peripheral vascular 
disease, muscle weakness, falls, and the administration of psy- 
choactive medications.2,3,10–14  Thus, abnormalities of bone in 
terms of both quality and quantity, variable biochemical ab- 
normalities, and multiple comorbid conditions are likely to 
contribute to the pathogenesis of fractures in ESRD. The com- 
plexity and nature of CKD-mineral and bone disorder (MBD) 
may also render conventional therapy for osteoporosis and 
osteopenia ineffective or possibly harmful in CKD or ESRD. 
Secondary hyperparathyroidism is known to be associated 
with renal osteodystrophy. However, it is unclear whether the 
incidence of fractures in patients receiving 
and effect on the risk of severe unremitting hyperparathyroid- 
ism23  were previously published. The trial population was di- 
verse in terms of age, sex, race/ethnicity, and comorbidity; the 
median dialysis vintage was 45.3 months.22   Baseline demo- 
graphic, medication, and laboratory values pertinent to fracture 
risk are listed in Table 1. Using an unadjusted intention-to-treat 
analysis, the effect of cinacalcet on the primary composite end 
point, composed of all-cause mortality or ﬁrst nonfatal cardio- 
vascular event (myocardial infarction, hospitalization for unsta- 
ble angina, heart failure, or peripheral vascular event), was not 
statistically signiﬁcant (relative hazard, 0.93; 95% conﬁdence 
interval [95% CI], 0.85 to 1.02).24 
 
Fracture Events during the Study 
Radiographic imaging was not routinely performed; thus, all 
fracture events were reported by study sites and thus should be 
considered clinical fractures. During the trial, 667 fractures 
dialysis has decreased in recent years despite 
active treatment of secondary hyperparathy- 
Table 1.   Baseline demographics, medical history, medication use, and 
laboratory values for the EVOLVE study participants 
roidism.15–18  Most previous studies of frac- 
ture in CKD and ESRD were cross-sectional 
 
Demographic 
Cinacalcet Group 
(n=1948) 
Placebo Group 
(n=1935) 
or had limited follow-up, and/or fracture as- 
sessment was made from claims data rather 
than prospectively collected or adjudicated. 
Importantly, despite the availability and 
widespread use of phosphate binders and vi- 
tamin D sterols, no randomized controlled 
trials evaluated whether any drug or other 
therapeutic strategies (e.g., parathyroidec- 
tomy) lowered the risk of fracture in CKD 
and/or ESRD. 
The objectives of this analysis were to 
determine fracture sites, frequency of and 
risk factors for clinical fracture events, and 
the effect of cinacalcet on clinical fracture 
rates in patients receiving hemodialysis 
with moderate to severe secondary hyper- 
parathyroidism using data from the Eval- 
uation of Cinacalcet HCl Therapy to Lower 
Cardiovascular Events (EVOLVE) trial.19 
We hypothesized that secondary hyper- 
parathyroidism is a major cause of bone 
Age (yr) 55.0 (35.0, 74.0) 54.0 (35.0, 73.0) 
Women  41.5  39.7 
Body mass index (kg2/m2) 26.3 (20.4, 36.4) 26.4 (20.6, 36.7) 
Region 
Australia 3.8 3.9 
Canada 3.7 3.8 
Europe 30.7 30.5 
Latin America 17.7 17.7 
Russia 7.3 7.2 
United States 36.7 37.0 
Race 
Black 21.0 22.1 
White 57.7 57.7 
Other 21.3 20.2 
Medical history 
Dialysis vintage (mo) 45.4 (8.5, 142.0) 45.1 (9.8, 149.6) 
Tobacco use 
Never 55.7 56.7 
Former 28.1 26.7 
Current 16.0 16.5 
Proton pump inhibitor use 30.2 28.6 
Vitamin D use 59.3 59.6 
Hormone replacement therapy 7.7 7.3 
loss and increased bone frag ilit y, and 
therefore treatment with cinacalcet would 
Calcium-containing phosphate 
binder use 
53.2 53.0 
reduce clinical fractures. 
 
 
RESULTS 
 
Baseline Characteristics 
Alcohol use 16.9 18.6 
Laboratory parameters 
Serum albumin (g/dl)    3.7 (3.2, 4.1)    3.7 (3.2, 4.1) Serum 
BALP (ng/ml)  23.1 (11.5, 71.0)  22.9 (11.5, 66.6) 
Serum calcium (mg/dl)    9.8 (9.0, 10.7)    9.8 (9.0, 10.7) 
Plasma intact PTH (pg/ml) 694.5 (362.0, 1707.0) 690.0 (363.0, 1683.0) 
Serum phosphorus (mg/dl) 6.3 (4.9, 8.3) 6.2 (4.9, 8.4) 
The baseline characteristics of the popula- 
tion,20   trial design,21  disposition of trial 
Serum 25-hydroxy cholecalciferol 
(mg/L) 
17.0 (8.0, 37.0) 18.0 (8.0, 38.0) 
participants (Consolidated Standards of Re- 
porting Trials diagram), primary results,22 
Data are presented as a percentage or median (10th percentile, 90th percentile). Adapted from 
Chertow et al.20 
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were reported; 622 (93.7%) were adjudicated as true fracture 
events by the Clinical Events Committee. There were 493 patients 
that experienced at least one conﬁrmed fracture (255 of 1935 
[13.2%] randomized to placebo and 238 of 1948 [12.2%] 
randomized to cinacalcet). Fifty-nine participants experienced 
two fractures (29 and 30 in the placebo and cinacalcet groups, 
respectively) and 29 experienced three or more fractures (14 and 
15 in the placebo and cinacalcet groups, respectively). 
 
Fracture Sites 
More than one-half of fractures in both groups involved pre- 
dominantly cortical bone at nonhip sites. Supplemental Table 1 
shows the total number of fracture events by site and incidence 
rates stratiﬁed by age, sex, and race. Figure 1 shows the unad- 
justed incidence of fractures by site, age, and randomized treat- 
ment assignment. Vertebral fractures were recorded in only 
1.2% of the total patient population, in a total of 51 fracture 
events, almost certainly an underestimate because screening ra- 
diographs were not performed. 
 
Clinical Fracture Rates 
Cumulative clinical fracture rates were 4.7 (95% CI, 4.2 to 5.3) 
and 4.3 (95% CI, 3.8 to 4.8) per 100 patient-years in the placebo 
and cinacalcet groups, respectively. As shown  in Figure 1, clinical 
fracture rates in patients aged ,65 years were virtually identical 
(3.8; 95% CI, 3.3 to 4.4) in both groups. However, among pa- 
tients aged $65 years, clinical fracture rates were 8.6 (95% CI, 
7.1 to 10.4) in the placebo group and 6.0 (95% CI, 4.8 to 7.3) in 
the cinacalcet group (P,0.01). Figure 2 shows the cumulative 
incidence plot of time to ﬁrst fracture for patients aged ,65 years 
and patients aged $65 years using an intention-to-treat analysis. 
Effect of Cinacalcet on First Clinical Fracture 
Intention-to-Treat Analyses 
As previously  reported using an unadjusted intention-to-treat 
analysis,22 the effect of cinacalcet on clinical fracture was not 
statistically signiﬁcant (relative hazard, 0.89; 95% CI, 0.75 to 
1.07). Despite randomization, median age was higher in pa- 
tients randomized to cinacalcet, as was the proportion of el- 
derly patients.22 After adjustment for age and other baseline 
characteristics, including fracture-related risk factors (previ- 
ous fracture, history of tobacco use, provision of hormone 
replacement therapy and proton  pump inhibitors, along 
with bone-related laboratory values), the relative hazard 
was 0.84 (95% CI, 0.69 to 1.01; P=0.07) (Table 2). Older 
age, female sex, diabetes, history of stroke and previous frac- 
ture, and tobacco use were associated with an increased rate of 
fracture, as were higher baseline bone-speciﬁc alkaline phos- 
phatase (BALP), higher baseline serum calcium, and higher 
and lower baseline plasma parathyroid hormone (PTH) (Table 2). 
Supplemental Figure 1 shows a Forest plot for ﬁrst clinical 
fracture by prespeciﬁed baseline clinical characteristics, and 
Supplemental Figure 2 shows the same by cointerventions for 
CKD-MBD using the multivariable-adjusted intention-to- 
treat analyses. 
 
 
Lag-Censoring Analysis 
As previously reported, more than two-thirds of patients in 
both  groups discontinued the study drug for a variety of 
protocol-speciﬁed  and  nonprotocol-speciﬁed  reasons.22  
Moreover, kidney transplantation and provision of PTH- 
lowering therapies (parathyroidectomy and off-protocol use 
of cinacalcet) were more common in patients randomized to 
placebo. Using a prespeciﬁed lag-censoring 
analysis (censoring time .6 months after 
stopping the study drug), the relative haz- 
ard for fracture was 0.72 (95% CI, 0.58 to 
0.90; P=0.003) (Supplemental  Table 2). 
Figure 3 shows effect modiﬁcation by pre- 
speciﬁed baseline clinical characteristics, 
and Figure 4 shows effect modiﬁcation by 
cointerventions for CKD-MBD. Using the 
lag-censoring approach, the relative bene- 
ﬁt of cinacalcet (or the relative harm of 
placebo plus conventional therapy) was 
more pronounced in patients treated with 
calcium-based phosphate binders (relative 
hazard, 0.55; 95% CI, 0.40 to 0.74; P=0.01) 
than in patients not treated, or treated with 
other, noncalcium-based phosphate binders 
(relative hazard, 0.98; 95% CI, 0.72 to 1.35). 
The relative beneﬁt of cinacalcet appeared 
to be more pronounced  among patients 
w i t h  ba se line dialysat e ca l c i um  $3. 0 
Figure 1. Unadjusted fracture rates by site, age, and treatment group. Fractures are 
more common at nonhip cortical sites compared with the hip, and are more common in 
patients aged $65 years. Bar graphs represent the mean6SD. 
mEq/L, although the interaction (treat- 
ment group3dialysate  calcium) was not 
signiﬁcant (P=0.15). 
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and 0.69 (95% CI, 0.49 to 0.95) in patients 
aged $65 years (P value for treatment by 
age [continuous] interaction, P=0.06). Fig- 
ure 3 shows unadjusted relative hazards 
using the lag-censoring approach; corre- 
sponding adjusted relative hazards were 
0.79 (95% CI, 0.58 to 0.90) and 0.60 (95% 
CI, 0.41 to 0.88), with a corresponding in- 
teraction P=0.28. 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Cumulative incidence of fractures. Cumulative incidence of clinical fractures 
in patients aged ,65 years (top) and aged $65 years (bottom). Patients randomized to 
cinacalcet are shown with the solid  line, and patients  randomized to placebo are 
shown with the dashed line. 
In  the  EVOLVE trial, we compared  the 
relative safety and efﬁcacy of cinacalcet and 
placebo along with conventional therapy 
for secondary hyperparathyroidism (typi- 
cally phosphate  binders  and  vitamin  D 
sterols). The primary composite end point 
of the  trial was all-cause mortality and 
nonfatal cardiovascular events; however, 
clinical fracture was a key secondary out- 
come, and reported fracture events were 
adjudicated along with major cardiovascu- 
lar end points. Because we did not screen 
for fractures at baseline or  at any ﬁxed 
intervals or routinely perform imaging 
analysis to  assess for  vertebral fractures 
that are often asymptomatic,25 we almost 
certainly ascertained just a small fraction 
of all fractures that occurred during the 
trial. Moreover, the trial was powered for 
its adjudicated cardiovascular composite 
end point. Had our assumptions held, we 
would have had relatively low power to 
detect a clinically meaningful difference 
in all clinical fractures. Power was further 
Censoring at Cointerventions 
When we censored at time of the cointerventions of para- 
thyroidectomy, kidney transplant, or provision of commercial 
cinacalcet, the relative hazard of fracture was 0.71 (95% CI, 0.58 
to 0.87, P=0.001) (Supplemental Table 3). 
 
Effect of Cinacalcet on Cumulative Clinical Fractures 
When considering the risk of all clinical fractures (ﬁrst plus 
subsequent) during the study, the unadjusted and multivariable- 
adjusted relative hazards (cinacalcet versus placebo) were 0.89 
(95% CI, 0.76 to 1.05; P=0.16) and 0.83 (95% CI, 0.72 to 0.98; 
P=0.02). Using the lag-censoring approach, the relative hazard 
was 0.77 (95% CI, 0.63 to 0.94; P=0.01) (Supplemental Table 4). 
 
Effect of Cinacalcet on Clinical  Fractures in Older Versus 
Younger Patients 
The adjusted relative hazards for clinical fractures by intention 
to treat were 0.92 (95% CI, 0.73 to 1.16) in patients aged ,65 years 
reduced by very high rates of discontinuation of the study 
drug in both groups (actually higher in the placebo group), 
high rates of kidney transplantation in younger patients, and 
differential application of parathyroidectomy and commer- 
cial (off-protocol) cinacalcet in patients randomized to pla- 
cebo compared with cinacalcet, as previously detailed.22 
Despite factors reducing the power to detect a difference, 
the results in this secondary analysis were consistent across 
unadjusted, multivariable-adjusted, lag-censoring, and PTH- 
lowering event–censoring analyses, with point estimates of 
the rate reduction ranging from 16% to 29% in patients ran- 
domized to cinacalcet when differences in baseline character- 
istics (principally in age) were accounted for. These ﬁndings 
were nominally signiﬁcant for the adjusted intention-to-treat 
analysis of cumulative fractures, and for both lag-censoring 
analyses (time to ﬁrst fracture, and cumulative fractures). 
The incidence of clinical fractures in this study was .4% per 
year. Two cross-sectional studies in dialysis patients found that 
www.jasn.org CLINICAL RESEARCH 
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Table 2.   Multivariable Cox regression of the effect of cinacalcet on the occurrence of ﬁrst clinical fracture, by intention-to- 
treat analysis 
Variablea  Relative Hazard (95% CI) P Value 
 
Treatment (cinacalcet/placebo) 0.84 (0.69 to 1.01) 0.07 
Age (yr)b 1.38 (1.22 to 1.55) ,0.001 
Sex (ref=women) 0.78 (0.64 to 0.96) 0.02 
Race (ref=white)   
Black 0.48 (0.35 to 0.66) ,0.001 
Other 0.75 (0.57 to 1.00) 0.05 
Geographical region (ref=United States)   
Russia 0.49 (0.30 to 0.82) 0.01 
Latin America 1.03 (0.72 to 1.47) 0.87 
Europe 0.76 (0.57 to 1.02) 0.06 
Canada 0.97 (0.62 to 1.50) 0.89 
Australia 0.59 (0.34 to 1.04) 0.07 
Tobacco use (ref=never) 
Current 1.54 (1.18 to 1.99) 0.001 
Former 0.91 (0.72 to 1.15) 0.43 
Dialysis vintage (yr) 
Type of vascular access (ref=natural  ﬁstula) 
1.05 (0.95 to 1.15) 0.35 
Permanent catheter 1.46 (1.09 to 1.94) 0.01 
Graft 1.51 (1.15 to 1.96) 0.003 
Other 1.35 (0.74 to 2.49) 0.33 
Alcohol use 1.39 (1.10 to 1.76) 0.01 
Calcium-containing phosphate binder use 1.16 (0.95 to 1.42) 0.14 
Hormone replacement therapy 1.26 (0.94 to 1.70) 0.13 
Proton pump inhibitor use 1.19 (0.97 to 1.47) 0.09 
History of cardiovascular diseasec 0.95 (0.61 to 1.48) 0.83 
History of peripheral vascular disease 0.84 (0.64 to 1.11) 0.23 
Other cardiac disease history (valvular heart disease and angina) 1.27 (1.02 to 1.58) 0.03 
Amputation history 0.87 (0.56 to 1.36) 0.54 
History of diabetes 1.46 (1.15 to 1.83) 0.002 
History of bone fracture 1.67 (1.36 to 2.06) ,0.001 
History of stroke 1.67 (1.29 to 2.17) ,0.001 
Hemoglobin 0.99 (0.89 to 1.09) 0.78 
Serum phosphorus (mg/dl) 1.07 (0.96 to 1.18) 0.23 
Serum calcium (corrected) (mg/dl) 1.11 (1.01 to 1.23) 0.03 
Serum BALP (ng/ml) 1.09 (1.00 to 1.20) 0.05 
Serum 25-hydroxy cholecalciferol (mg/L) 1.00 (0.90 to 1.12) 0.99 
Plasma intact PTH (pg/ml)d   
Log transformed 0.04 (0.00 to 0.76) 0.03 
Squared log transformed 1.28 (1.02 to 1.60) 0.04 
ref, reference value. 
aBoth treatment and BALP have time-dependent effect; the effects shown in the table are time-averaged effects. Unless otherwise speciﬁed, all continuous var- 
iables were standardized; one unit is equivalent to 1 SD. 
bAge by treatment interaction was not statistically signiﬁcant (P=0.06). 
cHistory of cardiovascular disease includes history of coronary artery disease, cardiac arrhythmia, coronary artery bypass graft, hypertension, heart failure, and 
myocardial infarction. 
dThe hazard ratios of the linear and squared PTH terms should be interpreted together and indicate that PTH had a nonlinear association with fractures; fracture rate 
is increased at the lower and higher ends of baseline PTH in this group of patients with secondary hyperparathyroidism. 
 
 
21% of patients in each patient population had prevalent ver- 
tebral fractures.26,27 The clinical fracture rates observed in the 
EVOLVE trial were slightly higher than in analyses from the 
prospective observational Dialysis Outcomes and Practice Pat- 
terns Study (DOPPS), in which the reported incidence was 
2.6% per year when reported in 2006,3 and was 3% in a 
more recent DOPPS III report with a median follow-up of 
only 1.6 years.4 Readers should be reminded that patients 
enrolled in the EVOLVE trial were of longer dialysis vintage, 
and had more severe secondary hyperparathyroidism than the 
general hemodialysis population, perhaps explaining these 
differences. In this study, and in both of these DOPPS obser- 
vational studies,3,28  fractures increased in older age groups. 
Fracture rates were much higher in older compared with 
younger patients, as virtually all other studies in the general 
population and CKD and ESRD populations have shown. The 
CLINICAL RESEARCH www.jasn.org 
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Figure  3. Forest plot  of treatment effect of cinacalcet on clinical fracture rate by prespeciﬁed baseline characteristics using lag- 
censoring analysis. HR, hazard ratio. 
 
 
effect of cinacalcet appeared to be more pronounced in older 
patients. Although effect modiﬁcation by age (the treatment3 
age interaction) was not statistically signiﬁcant, the power to 
detect interventions with a relatively small number of events 
and a modest overall treatment effect is quite low. This obser- 
vation could be explained by one of several factors: a true 
difference in the treatment effect, bias introduced by differen- 
tial application of cointerventions (including kidney trans- 
plantation, parathyroidectomy, and provision of commercial 
cinacalcet), differential susceptibility to the effects of second- 
ary hyperparathyroidism for which cinacalcet is prescribed, or 
lower event rates in younger patients, reducing statistical 
power. Given the high mortality, increased hospitalization 
rates, and costs associated with fractures,3,28–30 our study sug- 
gests that a reduction in fractures could have important per- 
sonal health and societal ﬁnancial beneﬁts. 
Given the mechanism of action of cinacalcet to reduce PTH 
release, it is probable that improvements in secondary hyper- 
parathyroidism led to the observed effects on clinical fracture 
rates. This is further supported by the association between 
baseline increased BALP (indicating higher bone turnover) and 
fracture. The reduction in clinical fractures observed with 
cinacalcet treatment in this study was similar to that observed 
in a case control study of surgical parathyroidectomy in the United 
States that demonstrated a 32% reduction in subsequent hip 
fractures.31 The importance of PTH as a biomarker of abnormal 
bone is controversial.32,33 Cohort studies have shown an increased 
risk of fracture associated with low PTH12,29,30  or very high 
PTH.3,12,30,34 Some studies have found no signiﬁcant relation to 
PTH.35,36   A meta-analysis suggested a direct effect of PTH.37 
These apparently conﬂicting results may be attributable to the 
relative short t1/2  and normal oscillatory release of PTH such 
that a single value may not predict future outcomes. The results 
of this study evaluating the effect of cinacalcet, which reduces 
PTH,38  on reducing fracture rates supports an important role 
of PTH in the pathogenesis of fractures in patients with CKD. 
This study demonstrated that nonhip cortical fractures were 
more common than hip fractures, although we did not search 
for radiographic evidence of asymptomatic spine fractures. We 
therefore cannot assume that cinacalcet exerts a similar effect 
on predominately cancellous bone sites such as the spine. Hy- 
perparathyroidism predominately reduces cortical bone 
area39,40  and measures of cortical bone by dual x-ray absorp- 
tiometry or computed tomography are more predictive of 
www.jasn.org CLINICAL RESEARCH 
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Figure 4. Forest plot of treatment effect of cinacalcet on clinical fracture rates by concomitant medications using lag-censoring analyses. 
HR, hazard ratio. 
 
 
fractures than other sites.41,42 In humans with secondary hyper- 
parathyroidism, parathyroidectomy improves bone mineraliza- 
tion, reduces osteoclast bone resorption, enhances osteoblast 
bone formation, and leads to osteocytic death (thereby improv- 
ing osteocytic osteolysis).43,44 In a uremic rat model with sec- 
ondary hyperparathyroidism, treatment with a calcimimetic 
agent reduced osteitis ﬁbrosa cystica, increased cortical bone 
mineral density, and corrected the CKD-induced loss of diaph- 
yseal stiffness.45 In a different rat model of CKD, elevated PTH 
led to increased cortical porosity and increased fragility assessed 
by three-point bending studies.46 However, even in the absence 
of PTH, there were cortical bone abnormalities and fragility due 
to altered collagen crosslinking in CKD rats.47 Our trial did not 
utilize bone imaging or bone biopsy; thus, abnormalities of bone 
quality and the mechanism(s) of the observed effects of cinacalcet 
cannot be deﬁnitely determined. However, the results of this 
study, previous imaging studies, and experimental studies in 
animals are compatible with the construct that cortical bone 
may be preferentially altered in CKD/ESRD. 
The strengths of these analyses include a randomized design, 
relatively large sample size, continued follow-up throughout the 
trial in 95% of participants, diversity (in age, sex, race/ethnicity, 
and clinical features of ESRD), breadth of comorbidity, labora- 
tory  data  available at  study entry,  and  most  importantly, 
adjudication of clinical fracture end points by a trained Clinical 
Events Committee blinded to treatment assignment and other 
clinical features such as laboratory data. There are also several 
important limitations. By design, only patient-reported clinical 
fractures were identiﬁed; by not screening for asymptomatic 
fractures, we probably ascertained a small fraction of the fractures 
sustained by patients during the trial. We did not distinguish 
traumatic from atraumatic fractures and falls are a major de- 
terminant of fractures.13 Unfortunately, we did not collect data on 
muscle strength, falls, or physical activity in the EVOLVE trial. 
Although we accounted for the use of selected concomitant med- 
ications (phosphate binders, vitamin D sterols, and several other 
drugs prescribed at baseline), it is possible that participants took 
other medications at baseline or throughout the trial that might 
have made clinical fractures more or less likely. A large number of 
participants stopped taking cinacalcet for both protocol-speciﬁed 
and nonspeciﬁed reasons. In addition, it is highly likely that the 
observed treatment effect was attenuated by reduced adherence 
to, and “crossover” of, treatment and was further confounded by 
the effects of kidney transplantation and parathyroidectomy. Fi- 
nally, the relatively small sample size may have precluded our 
ability to detect signiﬁcant interactions between cinacalcet use 
and age or other covariates. 
In summary, an unadjusted intention-to-treat analysis did 
not show a signiﬁcantly reduced risk of clinical fracture in the 
group randomized to cinacalcet. However, when accounting 
for differences in baseline characteristics, multiple fractures, 
and/or events prompting discontinuation of the study drug, 
cinacalcet reduced the rate of clinical fracture by 16%–29%. 
 
 
CONCISE METHODS 
 
Study Population  and Design 
In the EVOLVE trial, 3883 patients with secondary hyperparathy- 
roidism receiving hemodialysis were randomized 1:1 to receive either 
CLINICAL RESEARCH www.jasn.org 
8 Journal of the American Society of Nephrology J Am Soc Nephrol 26: ccc–ccc, 2014 
 
 
 
 
cinacalcet (Sensipar; Amgen Inc) or placebo in addition to conventional 
therapies for CKD-MBD (i.e., instructions for dietary phosphorus re- 
striction, phosphate binders, and vitamin D sterols).48 Eligible partic- 
ipants were on hemodialysis three times per week with plasma PTH 
concentrations $300 pg/ml (31.8 pmol/L), serum calcium phosphate 
product $45 mg2/dl2 (3.63 mmol2/L2), and serum calcium $8.4 mg/dl 
(2.1 mmol/L). The dose of the study drug was titrated once every 4 weeks 
during the ﬁrst 20 weeks and every 8 weeks during the subsequent 
follow-up period (from a starting dose of 30 mg to a maximum dose of 
180 mg daily), depending on blood levels of PTH and calcium. The 
dialysis prescription, other medical procedures, and doses of phosphate 
binders, vitamin D sterols, calcium supplements, and other medications 
were administered at the discretion of the treating physicians. Rates of 
withdrawal from cinacalcet, often related to gastrointestinal symptoms, 
were high; crossover from placebo to commercially available 
cinacalcet also reduced the trial’s power to detect a statistically signiﬁ- 
cant result.22 The trial was led by an academic executive committee and 
was sponsored by Amgen Inc. Ethics committee approval was obtained 
at all participating sites; all patients gave informed consent. The 
EVOLVE trial is registered with ClinicalTrials.gov (NCT00345839). 
 
Clinical Fracture Events 
An independent Clinical Events Committee adjudicated all primary and 
secondary end points.22 Clinical fracture was a prespeciﬁed key second- 
ary end point. Clinical fractures were ascertained at each visit by study 
personnel. Furthermore, all adverse events were screened for all com- 
ponents of the primary and secondary end points, such that clinical 
fractures that might have occurred in conjunction with other events 
were submitted for adjudication. Routine radiographic imaging was 
not performed to detect asymptomatic fractures. For the purpose of 
our analyses, fracture events were categorized as clinical vertebral and 
nonvertebral fractures, the latter being further subdivided into hip frac- 
tures (femur and intertrochanteric/subtrochanteric), nonhip predomi- 
nantly cortical fractures (upper or lower extremities, ribs, or pelvis), and 
other nonvertebral fractures. 
 
Biochemical Determinations 
Biochemical markers of CKD-MBD including plasma intact PTH 
(normal range, 11–72 pg/ml) and serum concentrations of total cal- 
cium (8.3–10.6 mg/dl), phosphorus (2.2–5.1 mg/dl), 25-hydroxy vi- 
tamin D (11–72 ng/ml), and BALP (2.9–22.6  ng/ml) were analyzed 
at a central laboratory. 
 
Sample Size Determination 
Although the trial’s sample size was determined based on assump- 
tions surrounding the primary composite end point (time to death, 
nonfatal myocardial infarction, hospitalization for unstable angina, 
heart failure, or peripheral vascular event), we prospectively calcu- 
lated the power to detect differences in fracture rates based on the 
following assumptions: fracture rate of 4% per year in the placebo 
group, 1.5-year enrollment period, 4-year total study duration, lost to 
follow-up rate of 1% per year, a “drop-out” (withdrawal from treat- 
ment) rate of 10% per year in the cinacalcet group, and a “drop-in” 
(use of commercial cinacalcet) rate of 10% in the placebo group. 
Based on 3800 patients enrolled, we calculated the power to be 
approximately 60% to detect a 30% effect size using a two-sided 
a=0.044. 
 
 
Statistical Analyses 
The primary analysis for the effect of cinacalcet was conducted using 
the intention-to-treat principle. Prespeciﬁed secondary analyses in- 
cluded a multivariable proportional hazards (Cox) regression analysis 
adjusting for baseline characteristics, including age, sex, race (white, 
black, or other),  geographic region, history of diabetes mellitus, 
history of cardiovascular diseases, and other variables known to be 
related to fracture in the general population (previous fracture, 
smoking, or use of hormone replacement therapy). Further covariates 
were selected by a process of backward elimination. Additional 
prespeciﬁed secondary analyses included a lag-censoring analysis, in 
which follow-up time .6 months after discontinuation of the study 
drug was censored, and a prespeciﬁed analysis censoring at cointerven- 
tions of parathyroidectomy, transplantation, and administration of 
commercial cinacalcet in the placebo arm.22  We used fractional poly- 
nomial regression to examine the association of baseline PTH with 
fractures.49 To examine the effect of cinacalcet on serial clinical fracture 
events, we utilized the Prentice–Williams–Petersen extension of Cox 
regression. We tested for effect modiﬁcation by age, sex, race, geographic 
region, dialysis vintage (time since initiation of dialysis), diabetes, and 
baseline PTH using multiplicative interaction terms. We also explored 
whether the effect of cinacalcet on clinical fractures was more or less 
pronounced with differences in the prescription (at baseline) of phos- 
phate binders, vitamin D sterols, and dialysate calcium. 
All inference tests were performed without adjusting for multiple 
comparisons. Because the  effects of randomization  to  cinacalcet 
versus placebo on the primary composite end point did not reach 
statistical signiﬁcance on an unadjusted log-rank test,22 comparisons 
yielding two-tailed P values,0.05 were deemed nominally signiﬁ- 
cant. All statistical analyses were conducted at Stanford University 
using SAS 9.3 software (SAS Institute Inc., Cary, NC). 
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